GlassScriptPhysician profile
Joel Ledford
NPI 1164425732
$6,522.92
in general payments reported to CMS, 2019-2025
25 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,306 · 2022: $1,309 · 2023: $1,040 · 2024: $1,374 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.17 |
| Education | $132.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,436.49 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,276.87 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $933.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $614.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $407.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.89 | 2021-2023 | Spiriva Respimat |
| Amgen INC. | $251.76 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $246.75 | 2022-2025 | Xolair |
| Grifols USA, LLC | $202.25 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Incyte Corporation | $139.30 | 2022-2023 | Opzelura |
| Blueprint Medicines Corporation | $96.75 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $83.76 | 2021-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $77.90 | 2025 | Neffy |
| Alk-Abello, INC | $54.84 | 2021-2022 | |
| Lilly USA, LLC | $46.14 | 2025 | Ebglyss |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $46.13 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.77 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $31.65 | 2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $31.03 | 2021 | |
| Biocryst US Sales Co., LLC | $30.32 | 2023 | Orladeyo |
| Aimmune Therapeutics, INC. | $26.54 | 2021 | |
| Pfizer INC. | $22.56 | 2022 | |
| Leo Pharma INC. | $17.11 | 2022 | |
| Dermavant Sciences, INC. | $14.11 | 2023 | Vtama |
| Csl Behring | $13.13 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ledford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.